Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia

Leukemia. 2016 Apr;30(4):947-50. doi: 10.1038/leu.2015.136. Epub 2015 Jun 9.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Antineoplastic Agents / therapeutic use*
  • Gene Rearrangement*
  • Humans
  • Imidazoles / therapeutic use*
  • Leukemia / drug therapy*
  • Leukemia / genetics*
  • Leukemia / pathology
  • Male
  • Middle Aged
  • Phenotype
  • Prognosis
  • Pyridazines / therapeutic use*
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Pyridazines
  • ponatinib
  • FGFR1 protein, human
  • Receptor, Fibroblast Growth Factor, Type 1